Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport open-label extension for adult upper limb spasticity after stroke or traumatic brain injury
2010-019162-83Phase 3Completed
- Sponsor
- Ipsen
- Start
- Apr 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in upper extremity spasticity and spastic hemiparesis, sponsored by Ipsen. Primary endpoints: Long-term safety of repeated Dysport treatment and Safety endpoints. Started Apr 2011; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
upper extremity spasticityspastic hemiparesis
Beyond the preview
Go deeper on 2010-019162-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019162-83.